Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11075 Roselle St SAN DIEGO CA 92121-1204 |
Tel: | N/A |
Website: | https://www.tandemdiabetes.com |
IR: | See website |
Key People | ||
Kim D. Blickenstaff Chairman of the Board | Leigh A. Vosseller Chief Financial Officer, Executive Vice President, Treasurer | David B. Berger Chief Operating Officer, Executive Vice President, Assistant Secretary |
Susan M. Morrison Executive Vice President, Chief Administrative Officer | Elizabeth A. Gasser Executive Vice President, Chief Strategy Officer | Brian B. Hansen Chief Commercial Officer, Executive Vice President |
Shannon M. Hansen Senior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary | James A. Leal Senior Vice President - Operations | Rick Carpenter Chief Technical Officer |
Business Overview |
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The Company's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings. |
Financial Overview |
For the three months ended 31 March 2022, Tandem Diabetes Care Inc revenues increased 25% to $175.9M. Net loss increased from $5M to $14.7M. Revenues reflect Infusion sets segment increase of 36% to $54.7M, Pump segment increase of 17% to $95.8M. Higher net loss reflects Research and development - Balancing val increase of 81% to $28.8M (expense), Other Selling, general and administ. increase of 25% to $61.4M (expense). |
Employees: | 2,000 as of Dec 31, 2021 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,425M as of Mar 31, 2022 |
Annual revenue (TTM): | $737.67M as of Mar 31, 2022 |
EBITDA (TTM): | $24.54M as of Mar 31, 2022 |
Net annual income (TTM): | $5.90M as of Mar 31, 2022 |
Free cash flow (TTM): | $73.84M as of Mar 31, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 63,962,732 as of Apr 29, 2022 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |